Xellia to shift APIs production outside of Denmark

Lossmaking Danish pharma ingredients maker Xellia Pharmaceuticals said it could only survive against Chinese competition by moving many of its products to its plant there, thus dealing a blow to Brussels efforts to reduce dependence on Asia.

Xellia Pharmaceuticals, a global leader in the manufacturing of fermentation-based anti-infective active pharmaceutical ingredients (APIs), announced plans for a gradual closure and transition of its manufacturing operations in Copenhagen, Denmark, to facilities outside of Denmark. The phased migration of the company’s anti-infective products will take place over eight to 10 years to ensure a continuous, stable supply of critical medicines, culminating in the eventual retirement of its Copenhagen manufacturing site.

“Xellia Pharmaceuticals is committed to safeguarding the responsible production and reliable supply of our critical anti-infectives for patients worldwide who rely on them in the fight against infections. Resilient operations are key to ensuring we can continue to deliver on this for many years to come,” said Michael Kocher, chief executive of Xellia Pharmaceuticals.